Bend Research Inc. has announced the addition of a new current Good Manufacturing Practice (cGMP) spray-drying facility.
The new facility expands Bend Research’s capabilities and expertise in the area of development and manufacture of high-potency drug candidates.
The company’s new facility is well-suited for the manufacture of a wide range of compound types and safety classifications, ranging from inhalable biotherapeutics to oral solid form high-potency small molecules.
The facility is physically separated from the company’s other development and cGMP manufacturing facilities and is designed for high containment operations at the highest safety and quality standards, utilizing the latest best-practice design features, finishes and engineering controls at the equipment level.
“We’re excited to offer our clients expanded cGMP spray-drying capability for high-potency compounds,” said Rod Ray, Chief Executive Officer. “This facility will complement our small molecule cGMP spray drying capabilities.”
The new facility is only part of the Bend Research’s expansion plans as the company enters its next phase of strategic growth.
In addition to the new high-potency spray-drying facility, the company recently expanded its solid-dosage-form capability and purchased an additional building for future expansion of development and manufacturing capabilities.